Pacira Biosciences
PCRX
P/S ratio for Pacira Biosciences (PCRX)
P/S ratio as of April 2024 (TTM): 1.81
According to Pacira Biosciences 's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 1.81481. At the end of 2023 the company had a P/S ratio of 2.32.
P/S ratio history for Pacira Biosciences from 2011 to 2023
PS ratio at the end of each year
| Year | P/S ratio | Change |
|---|---|---|
| 2023 | 2.32 | -12.62% |
| 2022 | 2.66 | -46.32% |
| 2021 | 4.95 | -18.2% |
| 2020 | 6.05 | 34.19% |
| 2019 | 4.51 | -14.24% |
| 2018 | 5.26 | -18.62% |
| 2017 | 6.46 | 47.81% |
| 2016 | 4.37 | -61.53% |
| 2015 | 11.4 | -29.92% |
| 2014 | 16.2 | -28.26% |
| 2013 | 22.6 | 55.01% |
| 2012 | 14.6 | 53.5% |
| 2011 | 9.50 |
P/S ratio for similar companies or competitors
| Company | P/S ratio | P/S ratio differencediff. | Country |
|---|---|---|---|
 Zogenix ZGNX | N/A | N/A | 🇺🇸 USA |
 Recro Pharma
REPH | N/A | N/A | 🇺🇸 USA |
 Omeros Corporation OMER | N/A | N/A | 🇺🇸 USA |
 Flexion Therapeutics
FLXN | N/A | N/A | 🇺🇸 USA |
 Heron Therapeutics HRTX | 2.92 | 60.72% | 🇺🇸 USA |
 Cara Therapeutics
CARA | 1.77 | -2.28% | 🇺🇸 USA |